relacorilant · Corcept Therap · NDA 220641
Lifyorli (Copackaged)
Earliest generic entry, as listed
22 Dec 2041
Blocked by patent: US 12152028.
Listed patents · 10 unexpired
20 Orange Book listing rows for 10 patents. FDA lists a patent once for each use code, and lists its pediatric extension as a separate row.
| Patent | Claims | Expires |
|---|---|---|
| US 12152028 | drug product, use U-4457, U-4458, U-4459 | 22 Dec 2041 |
| US 12152028 listing row | drug product, use U-4457 · sets the listed date | 22 Dec 2041 |
| US 12152028 listing row | drug product, use U-4458 · sets the listed date | 22 Dec 2041 |
| US 12152028 listing row | drug product, use U-4459 · sets the listed date | 22 Dec 2041 |
| US 11285145 | use U-4457, U-4458, U-4459 | 26 May 2041 |
| US 11285145 listing row | use U-4457 | 26 May 2041 |
| US 11285145 listing row | use U-4458 | 26 May 2041 |
| US 11285145 listing row | use U-4459 | 26 May 2041 |
| US 12589094 | use U-4457, U-4458, U-4459 | 26 May 2041 |
| US 12589094 listing row | use U-4457 | 26 May 2041 |
| US 12589094 listing row | use U-4458 | 26 May 2041 |
| US 12589094 listing row | use U-4459 | 26 May 2041 |
| US 11464764 | drug product | 14 Apr 2040 |
| US 11925626 | drug product | 18 Dec 2039 |
| US 12514849 | drug product | 18 Dec 2039 |
| US 10456392 | use U-4457 | 24 May 2033 |
| US 11576907 | drug substance, drug product, use U-4457, U-4458, U-4459 | 24 May 2033 |
| US 11576907 listing row | drug substance, drug product, use U-4457 | 24 May 2033 |
| US 11576907 listing row | drug substance, drug product, use U-4458 | 24 May 2033 |
| US 11576907 listing row | drug substance, drug product, use U-4459 | 24 May 2033 |
| US 8859774 | drug substance, drug product | 24 May 2033 |
| US 9273047 | use U-4457, U-4458, U-4459 | 24 May 2033 |
| US 9273047 listing row | use U-4457 | 24 May 2033 |
| US 9273047 listing row | use U-4458 | 24 May 2033 |
| US 9273047 listing row | use U-4459 | 24 May 2033 |
Exclusivities · 1 unexpired
| NCE | new chemical entity (5 years) | 25 Mar 2031 |
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 220641 · 001 · RLD | capsule, oral | 100MG;25MG | 22 Dec 2041 |